

**BIOGRAPHICAL SKETCH**

NAME	POSITION TITLE
Edward Y. Zamrini	Associate Professor of Neurology, School of Medicine Director of Clinical Trials, Center for Alzheimer's Care, Imaging & Research University of Utah
eRA COMMONS USER NAME	
zamrini	

**EDUCATION/TRAINING**

INSTITUTION AND LOCATION	DEGREE	YEAR(s)	FIELD OF STUDY
American University of Beirut, New York, NY	BS	1977-79	Science
American University of Beirut, New York, NY	MD	1980-84	Medicine
Lutheran Medical Center, Brooklyn, NY	INTERN	1984-85	Internal Medicine
North Shore University Hospital, Manhasset, NY	RESIDENT	1985-88	Neurology
Medical College of Georgia Hospital, Atlanta, GA	FELLOW	1988-89	Neurogeriatrics
Medical College of Georgia Hospital, Atlanta, GA	FELLOW	1989-90	EEG - Epilepsy

**A. POSITIONS AND HONORS:**Employment / Experience

- 1990- 94 Clinical Assistant Professor of Psychiatry and Neurology, Medical College of Georgia, Augusta, GA
- 1994- 99 Clinical Associate Professor of Psychiatry and Neurology, Medical College of Georgia, Augusta, GA
- 1990- 99 Staff physician, VA Medical Center, Augusta, GA
- 1999- 99 Associate Professor of Psychiatry and Neurology, Medical College of Georgia, Augusta, GA
- 2000- 05 Assistant Professor of Neurology, University of Alabama at Birmingham, Birmingham, AL
- 2006- Associate Professor of Neurology, University of Utah, Salt Lake City, UT

Administrative and Other Experience

- 1987- 88 Chief Resident, Neurology, North Shore University Hospital, Manhasset NY
- 1989- 90 Consultant in Behavioral Neurology, Medical College of Georgia, Augusta, GA
- 1990- 99 Director, Geriatric Neuropsychiatry Program, VA Medical Center, Augusta, GA
- 1998- 99 Acting Chief, Dementia/Alzheimer's Program, VA Medical Center, Augusta, GA
- 2000- 04 Director, Information Transfer Core, Alzheimer's Disease Center, University of Alabama at Birmingham, Birmingham, AL
- 2003-now Member, Alzheimer's Disease Cooperative Study. Steering Committee Affiliate
- 2004- 05 Director, Clinical Core, Alzheimer's Disease Center, University of Alabama at Birmingham, Birmingham, AL
- 2005-now Ad Hoc reviewer, Medical Science Monitor International Reviewers
- 2006- Member, Center on Aging, University of Utah, Salt Lake City, UT
- 2006- Scientist, Brain Institute, University of Utah, Salt Lake City, UT
- 2006- Director of Clinical Trials, Center for Alzheimer's Care, Imaging and Research, University of Utah, SLC UT

Selected Honors and Awards

- 1992 Spirit Award, Augusta Chapter Alzheimer's Association
- 1992 PARFore Award (People Are Recognized for Excellence Award), VAMC, Augusta, GA
- 1993 Letter of commendation for commitment to service from the Director of VAMC-Augusta, GA
- 1994 Blue Ribbon Award, Augusta Chapter Alzheimer's Association
- 2007 Weber State University Exemplary Collaboration Award

**B. SELECTED PEER-REVIEWED PUBLICATIONS (in chronological order):**

- Sethi KD, Zamrini EY. (1990). Clinical Features of Drug-Induced Parkinsonism with Special Attention to Asymmetry. *Journal of Neuropsychiatry*, 2, 64-66. PMID1983774
- Ray PG, Meador KJ, Loring DW, Zamrini EW, Yang XH, Buccafusco JJ. (1992). Central anticholinergic hypersensitivity in aging. *J Geriatr Psychiatry Neurol*, 5(2), 72-7. PMID1317178

**SELECTED PEER-REVIEWED PUBLICATIONS (CONTINUED)**

3. Meador KJ, Loring DW, Abney OL, Allen ME, Moore EE, Zamrini EY, King DW. (1993). Effects of carbamazepine and phenytoin on EEG and memory in healthy adults. *Epilepsia*, 34(1), 153-7. PMID8422849
4. Meador KJ, Moore EE, Nichols ME, Abney OL, Taylor HS, Zamrini EY, Loring DW. (1993). The role of cholinergic systems in visuospatial processing and memory. *J Clin Exp Neuropsychol*, 15(5), 832-42. PMID8276939
5. Tompkins MM, Basgall EJ, Zamrini E, Hill WD. (1997). Apoptotic-like changes in Lewy-body-associated disorders and normal aging in substantia nigral neurons. *Am J Pathol*, 150(1), 119-31. PMID9006329
6. Griffith HR, Belue K, Sicola A, Krzywanski S, Zamrini E, Harrell L, Marson DC. (2003). Impaired financial abilities in mild cognitive impairment: a direct assessment approach. *Neurology*, 60(3), 449-57. PMID12578926
7. Thal LJ, Grundman M, Berg J, Ernstrom K, Margolin R, Pfeiffer E, Weiner MF, Zamrini E, Thomas RG. (2003). Idebenone treatment fails to slow cognitive decline in Alzheimer's disease. *Neurology*, 61(11), 1498-502. PMID14663031
8. Zamrini E. (2004). Alzheimer's Disease. In Faught Jr. RE (Ed.), *Year in Neurology, 2004*. Oxford: Clinical Publishing Services.
9. Zamrini E, McGwin G, Roseman JM. (2004). Association between statin use and Alzheimer's disease. *Neuroepidemiology*, 23(1-2), 94-8. PMID14739574
10. Zamrini E, Parrish JA, Parsons D, Harrell LE. (2004). Medical comorbidity in black and white patients with Alzheimer's disease. *South Med J*, 97(1), 2-6. PMID14746413
11. Grundman M, Petersen RC, Ferris SH, Thomas RG, Aisen PS, Bennett DA, Foster NL, Jack CR Jr, Galasko DR, Doody R, Kaye J, Sano M, Mohs R, Gauthier S, Kim HT, Jin S, Schultz AN, Schafer K, Mulnard R, van Dyck CH, Mintzer J, Zamrini EY, Cahn-Weiner D, Thal LJ. (2004). Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. *Arch Neurol*, 61(1), 59-66. PMID14732621
12. Zamrini E, De Santi S, Tolar M. (2004). Imaging is superior to cognitive testing for early diagnosis of Alzheimer's disease. *Neurobiol Aging*, 25(5), 685-91. PMID15172748
13. Mruthinti S, Buccafusco JJ, Hill WD, Waller JL, Jackson TW, Zamrini EY, Schade RF. (2004). Autoimmunity in Alzheimer's disease: increased levels of circulating IgGs binding Abeta and RAGE peptides. *Neurobiol Aging*, 25(8), 1023-32. PMID15212827
14. Davis LL, Weaver M, Zamrini E, Stevens A, Kang DH, Parker CR Jr. (2004). Biopsychological markers of distress in informal caregivers. *Biol Res Nurs*, 6(2), 90-9. PMID15388906
15. Thal LJ, Ferris AS, for the Alzheimer's Disease Cooperative Study. (2006). ADCS Prevention Instrument Project: Development of a Brief Verbal Memory Test for Primary Prevention Clinical Trials. *Alzheimer Disease and Associated Disorders*, 20(Suppl 3), S139-S146. PMID17135807
16. Griffith HR, Netson KL, Harrell LE, Zamrini EY, Brockington JC, Marson DC. (2006). Amnesic mild cognitive impairment: diagnostic outcomes and clinical prediction over a two-year time period. *J Int Neuropsychol Soc*, 12(2), 166-75. PMID16573850
17. Zamrini E. (). *Emerging Drug Therapies for Dementia*. *Geriatrics and Aging*, 9(2), 107,110-113.
18. Salmon DP, Cummings JL, Jin S, Sano M, Sperling RA, Zamrini EY, Petersen RC, Edland SD, Thal LJ, Ferris AS. (2006). ADCS Prevention Instrument Project: Development of a Brief Verbal Memory Test for Primary Prevention Clinical Trails. *Alzheimer Disease and Associated Disorders*, 20(3), S139-S146. PMID17135807
19. Rahman A, Baker PS, Allman RM, Zamrini E. (2007). Dietary Factors And Cognitive Impairment In Community-Dwelling Elderly. *Journal of Nutrition, Health and Aging*, 11(1), 49-54. PMID17315080
20. Okonkwo O, Griffith H.R, Belue K, Lanza S, Zamrini E, Harrell L.E, Brockington J.C, Clark D, Raman R, Marson D.C. (2007). Medical Decision-Making capacity in patients with mild cognitive impairment. *Neurology*. PMID18282327
21. Griffith HR, Den Hollander JA, Stewart CC, Evanochko WT, Buchthal SD, Harrell LE, Zamrini EY, Brockington JC. (2007). Elevated brain scyllo-inositol concentrations in patients with Alzheimer's disease. *NMR in Biomedicine*. PMID17295394

**C. RESEARCH SUPPORT:**

ONGOING RESEARCH SUPPORT:

- ADC030 Zamrini (PI) 9/1/07 - 12/31/12  
Alzheimer's Disease Cooperative Study (ADCS)  
Home-Based Assessment of Elderly at Risk for Cognitive Decline, Mild Cognitive Impairment and Alzheimer's Disease  
*Major goal(s):* Evaluate three methods of performing home-based assessments in AD prevention trials.  
Role: Principal Investigator
- U01-AG10483 Zamrini (PI) 8/1/08 - 1/31/11  
Pfizer/ADCS/NIH  
A Double-Blind, Placebo-Controlled, Randomized, Multicenter Study Evaluating the Efficacy & Safety of Eighteen Months Treatment with PF-04494700 (TTP488) in Participants with Mild to Moderate Alzheimer's Disease (RAGE)  
*Major goal(s):* Evaluate efficacy & safety of PF 04494700 in participants with mild to moderate AD.  
Role: Principal Investigator
- AAB-001-AD301 Zamrini (PI) 4/1/08 - 4/10/10  
Elan Pharmaceuticals, Inc.  
A phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy and safety trial of Bapineuzumab in patients with mild to moderate Alzheimer's disease who are apolipoprotein E4 non-carriers  
*Major goal(s):* Evaluate efficacy and safety of bapineuzumab in male and female patients aged 50 to 89 years with mild to moderate AD.  
Role: Principal Investigator
- AAB-001-AD302 Zamrini (PI) 4/1/08 - 4/10/10  
Elan Pharmaceuticals, Inc.  
A phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group, efficacy and safety trial of Bapineuzumab in patients with mild to moderate Alzheimer's disease who are apolipoprotein E4 non-carriers  
*Major goal(s):* Evaluate efficacy and safety of bapineuzumab in male and female patients aged 50 to 89 years with mild to moderate AD.  
Role: Principal Investigator
- ELND005-AD201 Zamrini (PI) 5/1/08 - 5/1/10  
Elan Pharmaceuticals, Inc.  
PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-RANGING, SAFETY AND EFFICACY STUDY OF ORAL ELND005 (AZD-103) IN ALZHEIMER'S DISEASE  
*Major goal(s):* Evaluate the dose-related safety and efficacy of multiple oral dosages of ELND005 as treatment for Alzheimer's disease.  
Role: Principal Investigator
- 51001866 Foster (PI) 11/01/06 - 10/31/09  
Anonymous Foundation  
Early Detection of Alzheimer's Disease in a Community Population Using Longitudinal Cognitive Assessment (Early AD Detection)  
*Major goal(s):* Validate with neuroimaging a new approach of using repeated neuropsychological measures to identify Alzheimer's disease (AD) while cognition is still nominally within normal limits. This is a collaborative, feasibility pilot study between investigators at the University of Utah and faculty at Utah State University involved in the Cache County Memory and Aging Study (CCMS).  
Role: Co-Investigator

Principal Investigator/Program Director (Last, First, Middle): Zamrini, Edward Y.

**ONGOING RESEARCH SUPPORT (CONTINUED)**

E2020-G000-326 Zamrini (PI) 6/1/07 - 6/1/08  
Eisai Medical Research Inc./ICON  
Double-Blind, Parallel-Group Comparison of 23 Mg Donepezil Sustained Release to 10 Mg Donepezil Immediate Release in Patients with Moderate to Severe Alzheimer's Disease  
*Major goal(s):* Compare 23 mg donepezil sustained release (SR) to the currently marketed formulation of 10 mg donepezil immediate release (IR) in patients with moderate to severe Alzheimer's disease.  
Role: Principal Investigator

H6L-MC-LFBC Zamrini (PI) 6/1/08 - 11/30/10  
Eli Lilly  
Effect of  $\gamma$ -Secretase Inhibition on the Progression of Alzheimer's Disease: LY450139 vs Placebo  
*Major goal(s):* Measure the effect of LY450139 on both (A $\beta$ ) and amyloid plaques in patients 55 years and older, using several different tests.  
Role: Principal Investigator

0512008265 Zamrini (PI) 5/1/08 - 6/30/10  
Baxter Bioscience/ADCS  
IGIV - A Randomized, Double-Bind, Placebo-Controlled, Two Dose-Arm, Parallel Study of the Safety and Effectiveness of Immune Globulin Intravenous (Human), 10% (IGIV, 10%) for the Treatment of Mild-to-Moderate Alzheimer's Disease: The Gammaglobulin Liquid for Alzheimer's Disease (GLAD) trial  
*Major goal(s):* Evaluate safety, efficacy and biological mechanisms of action of Intravenous Immunoglobulin (IVIg) in the treatment of mild to moderate stage Alzheimer's disease (AD).  
Role: Principal Investigator

**COMPLETED RESEARCH SUPPORT:**

MK0249011 Zamrini (PI) 10/27/06 - 11/30/08  
Merck & Co., Inc.  
A Randomized, Double Blind, Placebo Controlled, Parallel Group Trial to Evaluate the Safety and Efficacy of MK-0249 for the Symptomatic Treatment of Alzheimer's Disease  
*Major goal(s):* Test efficacy and safety of an investigational medication for improving symptoms of AD. Subjects receive active medication or placebo for 28 days, and undergo memory and concentration tests.  
Role: Principal Investigator

MPC-7869-05-010.01 Zamrini (PI) 10/1/06 - 10/1/08  
Myriad Genetics  
Phase 3 Multinational, Randomized, Double Blind, Placebo Controlled Study of the Effect of Daily Treatment with MPC-7869 on Measures of Cognition, Activities of Daily Living and Global Function in Subjects with Mild Dementia of the Alzheimer's Type  
*Major goal(s):* Evaluate change in cognitive ability and activities of daily living in patients with AD, as measured by specific evaluations during 18 months of dosing.  
Role: Principal Investigator

Zamrini (PI) 1/1/07-12/31/08  
University of Utah  
A Pilot Study of Magnetoencephalography in Alzheimer's Disease  
Role: Principal Investigator

1 R01 AG22394 Foster (PI) 9/30/03 - 7/31/08  
NIH/NIA  
Pilot Collaborative PET Imaging Trial  
*Major goal(s):* Perform a pilot multi-center clinical trial to validate FDG-PET as a diagnostic biomarker in frontotemporal dementia.  
Role: Co-Investigator